http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2017071879-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_be1ae1f965148e029f744bb55cf78832 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-137 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-135 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-135 |
| filingDate | 2015-09-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a1b44dc872f3b547c196fda71085dfbc |
| publicationDate | 2017-03-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2017071879-A1 |
| titleOfInvention | Prototypical analgesic profile of 3,3-diphenyl-n-(1-phenylethyl)propan-1-amine (fendiline) |
| abstract | The present invention discloses the prototypical profile of 3,3-diphenyl-N-(1-phenylethyl) propan-1-amine (fendiline) against the anticancer drugs induced neuropathic pain (ADINP). Indeed, fendiline exhibited high analgesic activity against the Paclitaxel induced neuropathic sensitization (PINS), in mice, and also inducing decrease of brain dopamine (DA) turnover, in rats and mice, i.e., the exactly opposite effects of those induced by the μ-opioid receptor agonists (μ-ORAs). Thus, the above properties of fendiline allow the beneficial synergy of fendiline and μ-ORAs, with fendiline reinforcing the analgesic properties of μ-ORAs and protecting against the opioid dependence and the neurotoxicity of μ-ORAs, coming from the increase of the brain DA turnover induced by the μ-ORAs. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2739376-C1 |
| priorityDate | 2015-09-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 54.